View Item 

Show simple item record

Effect of age on lipid profiles in pediatric heart transplant recipients
dc.contributor.authorArmstrong, Aimee K.en_US
dc.contributor.authorGoldberg, Caren S.en_US
dc.contributor.authorCrowley, Dennis C.en_US
dc.contributor.authorWei, Weien_US
dc.contributor.authorGajarski, Robert J.en_US
dc.date.accessioned2010-06-01T22:02:40Z
dc.date.available2010-06-01T22:02:40Z
dc.date.issued2005-08en_US
dc.identifier.citationArmstrong, Aimee K.; Goldberg, Caren S.; Crowley, Dennis C.; Wei, Wei; Gajarski, Robert J. (2005). "Effect of age on lipid profiles in pediatric heart transplant recipients." Pediatric Transplantation 9(4): 523-530. <http://hdl.handle.net/2027.42/75071>en_US
dc.identifier.issn1397-3142en_US
dc.identifier.issn1399-3046en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75071
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16048607&dopt=citationen_US
dc.format.extent158671 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherMunksgaard International Publishersen_US
dc.publisherBlackwell Publishing Ltden_US
dc.rights2005 Blackwell Munksgaarden_US
dc.subject.otherHeart Transplantationen_US
dc.subject.otherPediatricen_US
dc.subject.otherHyperlipidemiaen_US
dc.subject.otherImmunosuppressionen_US
dc.titleEffect of age on lipid profiles in pediatric heart transplant recipientsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Pediatric Cardiology, Department of Pediatrics and Communicable Diseases, University of Michigan Health System, Ann Arboren_US
dc.contributor.affiliationumDepartment of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USAen_US
dc.identifier.pmid16048607en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75071/1/j.1399-3046.2005.00330.x.pdf
dc.identifier.doi10.1111/j.1399-3046.2005.00330.xen_US
dc.identifier.sourcePediatric Transplantationen_US
dc.identifier.citedreferenceBecker DM, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988: 85: 632 – 638.en_US
dc.identifier.citedreferenceBallantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporin therapy on plasma lipoprotein levels. JAMA 1989: 262: 53 – 56.en_US
dc.identifier.citedreferenceBaan CC, Van Riemsdijk-Van Overbeeke IC, Balk AHMM, et al. Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-ß1 type I receptor expression. Clin Transplant 2001: 15: 276 – 283.en_US
dc.identifier.citedreferenceBallantyne CM, Masri BE, Morrisett JD, Torre-Amione G. Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Curr Opin Cardiol 1997: 12: 153 – 160.en_US
dc.identifier.citedreferenceAkhlaghi F, Jackson CH, Parameshwar J, Sharples LD, Trull AK. Risk factors for the development and progression of dyslipidemia after heart transplantation. Transplantation 2002: 73: 1258 – 1264.en_US
dc.identifier.citedreferenceAlonso DR, Starek PK, Minick CR. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol 1977: 87: 415 – 435.en_US
dc.identifier.citedreferenceKapadia SR, Nissen SE, Ziada KM, et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: A serial intravascular ultrasound study. J Am Coll Cardiol 2001: 38: 206 – 213.en_US
dc.identifier.citedreferenceBehrendt D, Ganz P, Fang JC. Cardiac allograft vasculopathy. Curr Opin Cardiol 2000: 15: 422 – 429.en_US
dc.identifier.citedreferenceBoucek MM, Edwards LB, Keck BM, et al. The registry of the International Society for Heart and Lung Transplantation: Fifth official pediatric report-2001 to 2002. J Heart Lung Transplant 2002: 21: 827 – 840.en_US
dc.identifier.citedreferenceSeipelt IM, Crawford SE, Rodgers S, et al. Hypercholesterolemia is common after pediatric heart transplantation: Initial experience with pravastatin. J Heart Lung Transplant 2004: 23: 317 – 322.en_US
dc.identifier.citedreferenceChin C, Rosenthal D, Bernstein D. Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. Pediatr Transplant 2000: 4: 193 – 199.en_US
dc.identifier.citedreferenceDifilippo S, Sassolas A, Sassolas F, Semiond B, Bozio A. Changes in serum cholesterol, lipoproteins and triglycerides after cardiac transplantation in children. Arch Mal Coeur Vaiss 2001: 94: 464 – 469.en_US
dc.identifier.citedreference13. National Center for Health Statistics. 2000 CDC Growth charts: United States. Available from: URL: http://www.cdc.gov/growthcharts.en_US
dc.identifier.citedreferenceExpert Panel on Blood Cholesterol Levels in Children and Adolescents. National cholesterol education program: Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992: S89: 525 – 584.en_US
dc.identifier.citedreferenceLaw YM, Yim R, Agatisa PK, et al. Lipid profiles in pediatric thoracic recipients are determined by the immunosuppressive regimens [abstract]. J Heart Lung Transplant 2002: 21: 172.en_US
dc.identifier.citedreferenceValantine HA. Role of lipids in allograft vascular disease: A multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant 1995: 14: S234 – S237.en_US
dc.identifier.citedreferenceChin C, Gamberg P, Miller J, Luikart H, Bernstein D. Efficacy and safety of atorvastatin after pediatric heart transplantation. J Heart Lung Transplant 2002: 21: 1213 – 1217.en_US
dc.identifier.citedreferenceWeis M. Cardiac allograft vasculopathy: Prevention and treatment options. Transplant Proc 2002: 34: 1847 – 1849.en_US
dc.identifier.citedreferenceFenster BE, Tsao PS, Rockson SG. Endothelial dysfunction: Clinical strategies for treating oxidant stress. Am Heart J 2003: 146: 218 – 226.en_US
dc.identifier.citedreferenceJarvisalo MJ, Toikka JO, Vasankari T, et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999: 147: 237 – 242.en_US
dc.identifier.citedreferenceMccrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: A multicenter, randomized, placebo-controlled trial. J Pediatr 2003: 142: 74 – 80.en_US
dc.identifier.citedreferenceStein EA, Illingworth DR, Kwiterovich PO, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: A randomized controlled trial. JAMA 1999: 281: 137 – 144.en_US
dc.identifier.citedreferenceDejongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002: 106: 2231 – 2237.en_US
dc.identifier.citedreferenceMccrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res 2002: 51: 715 – 721.en_US
dc.identifier.citedreferenceHanaka S, Abe T, Itakura H, Matsumoto A. Gene expression related to cholesterol metabolism in mouse brain during development. Brain Dev 2000: 22: 321 – 326.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1399-3046.2005.00330.x.pdf
Size:
154.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.